GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » EV-to-FCF

Medexus Pharmaceuticals (TSX:MDP) EV-to-FCF : 3.55 (As of May. 12, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medexus Pharmaceuticals's Enterprise Value is C$99.2 Mil. Medexus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$28.0 Mil. Therefore, Medexus Pharmaceuticals's EV-to-FCF for today is 3.55.

The historical rank and industry rank for Medexus Pharmaceuticals's EV-to-FCF or its related term are showing as below:

TSX:MDP' s EV-to-FCF Range Over the Past 10 Years
Min: -236.91   Med: -5.02   Max: 127.34
Current: 3.55

During the past 12 years, the highest EV-to-FCF of Medexus Pharmaceuticals was 127.34. The lowest was -236.91. And the median was -5.02.

TSX:MDP's EV-to-FCF is ranked better than
92.76% of 511 companies
in the Drug Manufacturers industry
Industry Median: 23.55 vs TSX:MDP: 3.55

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Medexus Pharmaceuticals's stock price is C$1.59. Medexus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.410. Therefore, Medexus Pharmaceuticals's PE Ratio for today is 3.88.


Medexus Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Medexus Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals EV-to-FCF Chart

Medexus Pharmaceuticals Annual Data
Trend Dec13 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.32 -22.62 -25.66 -10.61 -44.64

Medexus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.43 -44.64 13.21 8.20 4.27

Competitive Comparison of Medexus Pharmaceuticals's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's EV-to-FCF falls into.



Medexus Pharmaceuticals EV-to-FCF Calculation

Medexus Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=99.178/27.969
=3.55

Medexus Pharmaceuticals's current Enterprise Value is C$99.2 Mil.
Medexus Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$28.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medexus Pharmaceuticals  (TSX:MDP) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Medexus Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.59/0.410
=3.88

Medexus Pharmaceuticals's share price for today is C$1.59.
Medexus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.410.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Medexus Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals (TSX:MDP) Business Description

Traded in Other Exchanges
Address
35 Nixon Road, Suite 1, Bolton, ON, CAN, L7E 1K1
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.
Executives
Benoit Gravel Director